Skip to content

Based on my analysis of the GO-CAM model and relevant information from UniProt and literature, I'll now provide a comprehensive review of the GO-CAM model (gomodel:6348a65d00000093).

Review of GO-CAM Model: USP20 inhibition of NF-kappa-B signaling via TRAF6 deubiquitination (Human)

Model Overview

This GO-CAM model (gomodel:6348a65d00000093) represents a regulatory pathway involving USP20 (Ubiquitin-specific protease 20), ARRB2 (β-arrestin-2), and TRAF6 (TNF receptor-associated factor 6) in the context of NF-kappa-B signaling in humans. The model shows how USP20 inhibits NF-kappa-B signaling by deubiquitinating TRAF6.

Biological Content Assessment

The model accurately represents the mechanism described in the literature (PMID:26839314), where:

  1. USP20 (Q9Y2K6) has cysteine-type deubiquitinase activity (GO:0004843)
  2. USP20 acts on ARRB2 (P32121), which functions as a molecular adaptor (GO:0060090)
  3. USP20 negatively regulates TRAF6 (Q9Y4K3), which has ubiquitin protein ligase activity (GO:0061630)
  4. The ultimate outcome is negative regulation of canonical NF-kappaB signal transduction (GO:0043124)

The biological content is consistent with known protein functions in UniProt: - USP20 is known to attenuate TLR4-mediated NF-kappa-B signaling by cooperating with β-arrestin-2/ARRB2 and inhibiting TRAF6 autoubiquitination - ARRB2 functions as a molecular adaptor and is involved in negative regulation of NF-kappa-B signaling - TRAF6 is an E3 ubiquitin ligase that mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains important for NF-kappa-B activation

Model Structure and Causal Flow

The causal flow of the model follows a logical pattern: 1. ARRB2 functions as a molecular adaptor that positively regulates USP20's deubiquitinase activity 2. USP20's deubiquitinase activity directly negatively regulates TRAF6's ubiquitin ligase activity 3. The inhibition of TRAF6 leads to the negative regulation of canonical NF-kappaB signaling

The causal relationships use appropriate predicates: - RO:0002629 (directly positively regulates) for ARRB2's effect on USP20 - RO:0002630 (directly negatively regulates) for USP20's effect on TRAF6

Cellular Localization

The model correctly indicates that all activities occur in the cytoplasm (GO:0005737), which is consistent with the UniProt information for these proteins.

Evidence and References

The model uses appropriate evidence codes and references: - ECO:0000314 (direct assay evidence used in manual assertion) with PMID:26839314 for most functional assertions - ECO:0000305 (curator inference used in manual assertion) for cellular locations

Adherence to GO-CAM Best Practices

The model follows GO-CAM best practices: 1. Activities are connected via causal relationships 2. Each activity is enabled by a specific protein 3. Activities are part of appropriate biological processes 4. Activities are localized to cellular components 5. Evidence codes and references are provided

Areas for Improvement

While the model is generally well-constructed, there are a few aspects that could be enhanced:

  1. Redundant Representation: There appears to be some redundancy in the model. Activity "gomodel:6348a65d00000093/6348a65d00000094" (USP20 deubiquitinase activity) and activity "gomodel:6348a65d00000093/6348a65d00000115" (also USP20 deubiquitinase activity) seem to represent the same function enabled by the same protein. This could be consolidated for clarity.

  2. Detailed Molecular Mechanism: The model could be enhanced by including information about the precise ubiquitination sites on TRAF6 that are targeted by USP20, especially since the UniProt entry indicates that TRAF6 is polyubiquitinated on Lys-124.

  3. Connection to Wider Signaling Context: The model could be expanded to show how this regulatory mechanism connects to upstream TLR4 signaling and downstream NF-kappa-B activation events.

  4. Evidence Base: One causal association (between ARRB2 and USP20) has two instances of the same evidence, which is redundant. Additionally, there's a causal association with no evidence specified.

Summary and Conclusion

This GO-CAM model successfully represents a regulatory mechanism where USP20 inhibits NF-kappa-B signaling by deubiquitinating TRAF6, with ARRB2 serving as a molecular adaptor in this process. The model is biologically accurate, well-structured, and adheres to GO-CAM best practices.

The model effectively communicates the key regulatory interaction between these proteins and their role in attenuating inflammatory signaling. With minor improvements to address redundancy and expand the molecular detail, this would be an exemplary GO-CAM representation of this regulatory pathway.